Mobilization of long-term hematopoietic reconstituting cells in mice by the combination of stem cell factor plus granulocyte colony-stimulating factor

Abstract

In this study, we have compared the ability of recombinant human granulocyte colony-stimulating factor (rhG-CSF) alone and the combination of low doses of recombinant rat pegylated stem cell factor (rrSCF-PEG) plus rhG-CSF to mobilize peripheral blood progenitor cells (PBPCs) with long-term engrafting potential. Female recipient irradiated mice were transplanted with PBPCs from male mice that were mobilized with rhG-CSF alone (group A) or rrSCF-PEG plus rhG-CSF (group B). As previously shown, greater short-term survival resulted in group B compared with group A, with 80% and 40% survival at 30 days posttransplant, respectively. Both groups of animals showed long-term donor-derived engraftment in greater than 95% of animals, as determined by quantitative specific polymerase chain reaction amplification of a Y chromosome sequence from whole blood of the mice at 6 to 12 months posttransplantation. Analysis of individual granulocyte-macrophage colonies, picked up from semisolid methylcellulose culture of bone marrow cells from transplanted mice, resulted in detection of donor- derived DNA in 98% of colonies from group B mice compared with 81% from group A mice. These data show that cells with long-term potential are mobilized by rhG-CSF alone and the combination of rrSCF-PEG plus rhG- CSF. Furthermore, an increased number of cells with short-term and long- term engraftment potential was obtained with rrSCF-PEG plus rhG-CSF compared with rhG-CSF alone.

Growth factor release from dentine matrix by pulp‐capping agents promotes pulp tissue repair‐associated events

“…SCF has been shown to exert its biological functions by binding to, and activating, the receptor tyrosine kinase c-Kit and has been demonstrated to play an important role in haematopoiesis, amongst other physiological functions (Lennartsson & Ronnstrand 2012). SCF can induce liberation of primitive haematopoietic cells from the bone marrow into the blood (Fleming et al 1993, Yan et al 1994 and is used therapeutically to enhance the release of haematopoietic stem cells as an adjunctive therapy in patients undergoing chemotherapy and/or radiotherapy. Chemotaxis of cells involved in tissue repair is a fundamental process in the healing of any tissue; with evidence emerging that that cells involved in pulp tissue regeneration may not, in fact, only originate from local tissue niches, but may be haematopoietic or perivascular in origin (Feng et al 2011, Frozoni et al 2012.…”

Long-Term Transfer and Expression of the Human β-Globin Gene in a Mouse Transplant Model

“…PCR for PDGF B was used as a control for DNA loading, while Y chromosome analysis was used for reconstitution with donor cells (male donors to female recipients). 29…”

Characterization of peripheral blood progenitor cells (PBPC) mobilized by filgrastim (rHuG‐CSF) in normal volunteers: dose–effect relationship for filgrastim with the character of mobilized PBPC

“…However, it is uncertain whether a 200 g/m 2 dose of filgrastim is adequate to mobilize 'stem' cells which reconstitute long-term haemopoiesis and immune functions in the allogeneic setting. It remains to be seen whether combinations of filgrastim and other haemopoietic growth factor(s) release the 'stem' cells more effectively than filgrastim alone as indicated in animal models (de Reval et al, 1994;Yan et al, 1994). These remaining complex questions should be addressed in welldesigned clinical trials.…”